Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | EVP, Chief Commercial Officer | March 06, 2026 | March 10, 2026 |
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | SVP, Chief Commercial Officer | February 08, 2024 | February 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.16 · Expires 2036-03-05 | Direct | 97,947 |
Reported balance
After 2026-03-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-06 · Grant · Acquired 97,947 · Balance 97,947 F1: 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 28,493 |
Reported balance
After 2026-03-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-06 · Grant · Acquired 28,493 · Balance 28,493 F2: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F3: The restricted stock units vest in four equal annual installments beginning March 6, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F3: The restricted stock units vest in four equal annual installments beginning March 6, 2027.
LEXICON PHARMACEUTICALS, INC.
Report date February 08, 2024 · Filed February 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 227,130 |
Reported balance
After 2024-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-08 · Grant · Acquired 227,130 · Balance 227,130 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F2: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.15 · Expires 2034-02-08 | Direct | 227,130 |
Reported balance
After 2024-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-08 · Grant · Acquired 227,130 · Balance 227,130 F3: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
F2: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
F3: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2026 Filed Mar 10, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 28,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001996325-26-000002 · form4-03102026_060309.xml · derivative · entry 2 Garner Thomas · CIK 0001996325 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,493 Underlying: Common Stock · 28,493 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 6, 2027. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 6, 2027. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (Right to Buy) · Derivative | 97,947 | $0.00 Strike: $22.16 | $0.00 |
DisclosureSEC source: 0001996325-26-000002 · form4-03102026_060309.xml · derivative · entry 1 Garner Thomas · CIK 0001996325 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,947 Underlying: Common Stock · 97,947 shares Expires 2036-03-05 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 23:33 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 45,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028884 · form4-12102024_111227.xml · derivative · entry 2 Garner Thomas · CIK 0001996325 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,372 Underlying: Common Stock · 45,372 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit granted under the Plan represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 50% of the restricted stock units vest on December 9, 2026 and 25% vest on each of December 9, 2027 and December 9, 2028. F3 · derivative.expiration_date: 50% of the restricted stock units vest on December 9, 2026 and 25% vest on each of December 9, 2027 and December 9, 2028. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 23:33 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (Right to Buy) · Derivative | 235,849 | $0.00 Strike: $18.76 | $0.00 |
DisclosureSEC source: 0001415889-24-028884 · form4-12102024_111227.xml · derivative · entry 1 Garner Thomas · CIK 0001996325 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,849 Underlying: Common Stock · 235,849 shares Expires 2034-12-08 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option granted under the 2024 Equity Incentive Plan (the "Plan") will vest and become exercisable on December 9, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:14 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 227,130 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001127602-24-004460 · form4.xml · derivative · entry 2 Garner Thomas · CIK 0001996325 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,130 Underlying: Common Stock · 227,130 shares Expires 2034-02-08 F3 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:14 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 227,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004460 · form4.xml · derivative · entry 1 Garner Thomas · CIK 0001996325 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,130 Underlying: Common Stock · 227,130 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. F2 · derivative.expiration_date: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Read SEC document |
| October 09, 2023 Filed Oct 11, 2023 20:02 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 248,923 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001127602-23-025765 · form4.xml · derivative · entry 1 Garner Thomas · CIK 0001996325 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,923 Underlying: Common Stock · 248,923 shares Expires 2033-10-09 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (10/9/2024) and vests 1/48th per month for each month of service thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.